Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

101 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-14

Study Completion Date

2025-02-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A variety of in vivo experimental models have been established for the studies of human cancer using both cancer cell lines and patient-derived xenografts (PDXs). In order to meet the aspiration of precision medicine, the in vivo murine models have been widely adopted. However, common constraints such as high cost, long duration of experiments, and low engraftment efficiency remained to be resolved. The chick embryo chorioallantoic membrane (CAM) is an alternative model to overcome some of these limitations. The chick CAM is shown to be a robust model for both the inoculation of cell lines and grafting of patient tumors for drug therapy evaluations and target genes/pathways analysis.

The start-up INOVOTION has developed a unique, highly sensitive and reproducible CAM assay to graft human cancer cells/tumors in the chicken egg environment. INOVOTION's technology was validated for over 55 human tumor cell lines, including carcinomas, gliomas and melanomas, as well as over 30 reference drugs currently on the market.

At INOVOTION, the graft of human cancer cells on the chicken CAM is currently conducted manually. To scale-up, the process was recently automated. The automation performance was assessed on cancer cells lines. The objective of this study is to demonstrate that the automation of the INOVOTION process enables tumors' proliferation using patient samples (from tumor samples or circulating tumor cells) as grafting material.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells)

NCT04957602

Non Small Cell Lung Cancer

TERMINATED

Therapeutic Response Evaluation by CTC Expansion System

NCT04972461

Circulating Tumor Cells

UNKNOWN

Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)

NCT00826683

Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease

COMPLETED PHASE3

Pronostic and Predictive Value of EMT in Localized Lung Cancer

NCT03509779

NSCLC, Stage I, II, IIIA, IIIB Surgery Progression +1 more

RECRUITING

The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients

NCT02505139

Nasopharyngeal Neoplasms

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Metastatic Prostate Cancer Breast Cancer Lung Cancer Ovarian Cancer Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

6 cohort

Prostate Cohorte : Castrate resistant metastatic prostate cancer patient Breast cohort : HER2+ ou RH+ metastatic breast cancer patient Lung cohort : Non-small cell lung metastatic lung cancer patient Ovarian cohort : Ovarian cancer with peritoneal carcinomatosis Colorectal cohort : Colorectal cancer with peritoneal carcinomatosis Gastric cancer : Gastric cancer with peritoneal carcinomatosis

Group Type EXPERIMENTAL

Patient sampling.

Intervention Type PROCEDURE

One or several bio-specimens will be sampled depending on the cohort :

* Blood (40 ml)
* Pleural Fluid (40 ml)
* Peritoneal liquid (40 ml)
* Solid tumors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patient sampling.

One or several bio-specimens will be sampled depending on the cohort :

* Blood (40 ml)
* Pleural Fluid (40 ml)
* Peritoneal liquid (40 ml)
* Solid tumors

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18
* Signed consent
* prostate adenocarcinoma histologically proven
* metastatic situation
* at least 2 metastatic sites
* Evolutionary disease that requires a new treatment
* HER2+ or RH+ breast adenocarcinoma histologically proven
* metastatic situation
* at least 2 metastatic sites
* Evolutionary disease that requires a new treatment
* Non Small Lung cancer histologically proven
* metastatic situation
* at least 2 metastatic sites
* Evolutionary disease that requires a new treatment
* Ovarian cancer histologically proven
* Presence of peritoneal carcinomatosis (stage IIIC or IV); with or without presence of peritoneal fluid
* Colo-rectal cancer histologically proven
* Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid
* Evolutionary disease that requires a new treatment
* Gastric cancer histologically proven
* Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid